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Abstract
Background: Device-associated healthcare-associated infections (DA-HAIs) are a major problem in pediatric intensive
care units (PICUs). However, there are no data available regarding the incidences of DA-HAIs in PICUs in Japan and
their influences on length of PICU stay and mortality. The objective of this study was to investigate the incidences of
three common DA-HAIs in a PICU and their influences on length of PICU stay and mortality in Japan.
Methods: We performed a retrospective surveillance study over 12 months in a single PICU in Japan. First, we
investigated the incidences of three common DA-HAIs: central line-associated bloodstream infections (CLABSI),
ventilator-associated pneumonia (VAP), and catheter-associated urinary tract infection (CAUTI) by chart review,
according to the surveillance definitions of the Centers for Disease Control and Prevention/National Healthcare Safety
Network. Second, we compared patient characteristics, morbidity, and mortality between the patients with and
without DA-HAIs.
Results: Of all 426 patients admitted to the PICU, 73 % had a central venous catheter, 75 % had an endotracheal tube,
and 81 % had a urinary catheter during their PICU stay; the device utilization ratios per patient-days for these were 0.78,
0.53, and 0.44, respectively. In total, 28 patients (6.6 %) acquired at least one of the three DA-HAIs investigated, with an
overall incidence per 1000 patient-days of 11.2. The incidences of CLABSI, VAP, and CAUTI per 1000 device-days were
4.3, 3.5, and 13.6, respectively. The median length of PICU stay for the patients with DA-HAIs was 22.5 days, compared
with 2 days for those without DA-HAIs. Although there was no statistical difference, the mortality of the patients with
DA-HAIs was 7.1 %, whereas the mortality of the patients without DA-HAIs was 2.3 %.
Conclusions: This study showed the incidences of three common DA-HAIs in a PICU in Japan, and that they were
associated with a longer length of PICU stay.
Keywords: Device-associated healthcare-associated infection, Nosocomial, Bloodstream infection, Ventilator-associated
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Background
Device-associated healthcare-associated infections (DA-
HAIs) are a major problem in pediatric intensive care
units (PICUs). They are associated with prolonged
PICU stay and increased morbidity and mortality [1, 2].
Surveillance of DA-HAIs is important as an effective
tool for reducing their incidence [3]. Studies in PICUs
have reported the incidence of DA-HAIs to be 6.0–24.5 %
[1, 2, 4–9]. Central line-associated bloodstream infections
(CLABSI), ventilator-associated pneumonia (VAP), and
catheter-associated urinary tract infections (CAUTI) are
the three most common DA-HAIs [4, 5], with incidences
per 1000 device-days reported to be 2.0–18.8, 1.8–31.8,
and 5.1–5.8, respectively [2, 8–20]. Incidences vary among
studies, and studies in developing countries have reported
higher incidences of DA-HAIs of 15.5–24.5 % [2, 8, 9].
However, there are no data available for Japan regarding
the incidences of DA-HAIs and their influences on length
of PICU stay and mortality. The objective of this study
was to investigate the incidences of the three common
DA-HAIs (CLABSI, VAP, and CAUTI) in a PICU in Japan
and their influences on length of PICU stay and mortality.
Methods
A retrospective surveillance study at the single PICU
in a children’s hospital in Japan was conducted from
January 2013 to December 2013 at the Osaka Medical
Center and Research Institute for Maternal and Child
Health. Our unit is a closed PICU with eight beds for
medical and surgical pediatric patients. Postoperative
care of cardiovascular surgery, gastrointestinal surgery,
thoracic surgery, and neurosurgery, as well as general
medicine and hematology/oncology treatments were most
commonly performed in the PICU. During the daytime
shift, the staff consists of eight nurses (one nurse per bed)
and four physicians, whereas during the night shift, the
staff consists of four nurses (one nurse for every two beds)
and one physician.
This study was approved by the hospital’s Ethics
Committee. All patients admitted to the PICU during the
study period were included. Data were retrospectively
collected from medical records, including demographic
data, type of admission, type of surgery, number of
patients who had any type of infection at admission, use
of devices, number of days each device was in use, type of
endotracheal tube, site of infection, pathogen of infection,
length of PICU stay, and mortality up to 28 days after
discharge from the PICU. We calculated the pediatric
index of mortality 2 (PIM2), originally developed to
predict the death of groups but not of individual patients
[21], using the profiles and the data of each patient.
Three common DA-HAIs (CLABSI, VAP, and CAUTI)
were retrospectively diagnosed according to the Centers
for Disease Control and Prevention/National Healthcare
Safety Network (CDC/NHSN) surveillance definitions
[22]. An infection was defined as DA-HAI when
there was no evidence of infection at the time of
admission, when it appeared after 48 h of PICU
admission, and the infection was associated with a
device. Furthermore, as for patients with any infec-
tion at the time of admission, only when a change in
pathogen or symptoms strongly suggests the acquisi-
tion of a new infection; we defined this infection as
a DA-HAI. All patients were surveyed up to 48 h
following discharge from the PICU.
Definitions of DA-HAIs
Central line-associated blood stream infection
A bloodstream infection was defined as CLABSI when it
was associated with a central intravascular line. Diagnosis
included both laboratory-confirmed bloodstream infection
and clinical sepsis [22].
Laboratory-confirmed bloodstream infection
Laboratory-confirmed bloodstream infection was defined
when either of the following criteria was observed:
a) A recognized pathogen was cultured from one or
more blood cultures of a patient, and this pathogen
was not related to an infection at another site.
b) A patient had signs or symptoms of infection not
related to an infection at another site, and a common
skin contaminant (such as coagulase-negative
Staphylococcus) was cultured from two or more blood
cultures drawn on separate occasions.
Clinical sepsis
Clinical sepsis was defined when a patient ≤1 year of age
had signs or symptoms of infection, there was no apparent
infection at another site, a physician instituted treatment
for sepsis, and blood culture was negative or no blood
culture was performed.
Ventilator-associated pneumonia
Pneumonia was defined as VAP when it was associated
with mechanical ventilation through a tracheostomy
or by an endotracheal intubation within the 48-h
period before the onset of infection. Briefly, pneumo-
nia was defined when all of the below were satisfied.
a) There was new or progressive and persistent
infiltrate, consolidation, cavitation (for all ages), or
pneumatoceles (for infants ≤1 year of age) on a
chest radiograph.
b) A patient had one of the following signs or
symptoms: fever (temperature ≥38 °C), leukopenia
(<4000 white blood cells [WBC]/mm3) or
leukocytosis (≥12,000 WBC/mm3).
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c) There were at least two of the following signs or
symptoms: (1) new onset of purulent sputum or a
change in property of the sputum, (2) new onset or
worsening cough, dyspnea, or tachypnea, (3) rales or
bronchial breath sounds, or (4) worsening gas
exchange.
Catheter-associated urinary tract infection
CAUTI was briefly defined when either of the following
two criteria was met:
a) A patient with a urinary catheter (UC) had one or
more of the following signs or symptoms, with no other
recognized infection: fever (temperature ≥38 °C), urinary
urgency, frequency, dysuria, or suprapubic tenderness,
and this patient had a positive urine culture (≥105
colony-forming units per mL) with no more than two
pathogens isolated.
b) A patient with a UC had at least two of the following
signs or symptoms, with no other recognized infection:
fever (temperature ≥38 °C), urinary urgency, frequency,
dysuria, or suprapubic tenderness, and one of the following:
positive dipstick analyses for leukocyte esterase or nitrate,
pyuria (urine specimen with ≥10 WBC/mm3 or ≥3 WBC/
high power field of unspun urine), a pathogen observed on
Gram staining of unspun urine, and the physician instituted
appropriate therapy for a urinary tract infection.
Our clinical practice was as follows. At the time of
insertion of a central venous catheter (CVC), we cleaned
the skin with povidone-iodine and cover the puncture
site with a transparent dressing. A needleless closed
system was not implemented. The puncture site was not
periodically cleaned but was cleaned only if soiling was
observed. A blood culture was obtained through a vascular
catheter if it was difficult by venipuncture. Aspiration of
tracheal secretions was performed if required according to
the patient’s condition using an aseptic technique after
instilling normal saline into the endotracheal tube (ETT).
Attending nurses recorded the properties and amount
of sputum and a breath sound every time they aspirated
tracheal secretions. A closed suction system was not
routinely used. Prone positioning was often used for
chest physiotherapy to prevent atelectasis. A distal
tracheal aspirate through the ETT was cultured and
Gram stained if required. We used a closed drainage
system for urinary catheterization. A urine sample was
aseptically obtained from the sampling port of the UC
or by bladder catheterization if required. Attending
nurses recorded the temperature and respiratory rate of
patients at least every 2 h. Attending physicians and
nurses recorded symptoms of an infection such as
cough, urinary urgency, and suprapubic tenderness
when they recognized these symptoms.
The total number of patients admitted during the study
period, total number of patient-days, total number of
patients with each device, total number of device-days,
and number of patients with each DA-HAI were counted.
Device utilization ratios were calculated by dividing the
total number of device-days by the total number of
patient-days. The incidence of DA-HAI per 100 patients
was calculated by dividing the number of patients with
infections by the total number of patients and then
multiplying the result by 100. The incidences of
device-associated infections per 1000 device-days were
calculated by dividing the number of patients with the
infection by the total number of specific device-days
and then multiplying the result by 1000.
We compared backgrounds, length of PICU stay, and
mortality rates between the patients with and without DA-
HAIs. In addition, we compared standardized mortality
ratio (SMR), which is the quotient of the actual mortality
divided by the predicted mortality.
Categorical variables were evaluated using the chi-
square test or Fisher’s exact test. Continuous variables
were evaluated using the Wilcoxon rank sum test. We
used the median and the 25th and 75th percentiles for
describing the age and the length of PICU stay. Statistical
significance was defined to be P ≤ 0.05. The statistical
analyses were carried out using JMP version 10.0 (SAS
Institute Inc., Cary, NC, USA).
Results and discussion
During the study period, 426 patients were admitted to
the PICU for a total of 2672 patient-days. Table 1 lists the
demographic characteristics and the numbers of patients
admitted after elective surgery, as unplanned admissions,
or with any type of infection. In addition, the table shows
mean PIM2 values, the mortality up to 28 days after
discharge from the PICU during the study period, and
median length of PICU stay. The total device-days for
CVC, ETT, and UC are listed in Table 2. 73 % of the
patients had a CVC, 75 % an ETT, and 81 % a UC during
their stay in the PICU. Device utilization ratios per
patient-days are shown in Table 1.
Out of the 426 patients admitted, 28 (6.6 %) acquired
a DA-HAI (CLABSI, VAP, or CAUTI). The incidences of
each of these are provided in Table 2. Two patients
acquired CLABSI and CAUTI during one PICU stay.
Out of nine cases of CLABSI, only one case had
laboratory-confirmed infection, whereas the others had
clinical sepsis.
There was one case of laboratory-confirmed bloodstream
infection in which coagulase-negative Staphylococci were
cultured, and there were five cases of clinical sepsis; in each
case, coagulase-negative Staphylococci were cultured from
one blood culture. Staphylococcus aureus and Moraxella
catarrhalis were isolated in one case each of VAP; however,
in the other three cases the pathogen was not isolated.
Escherichia coli (19 %), Pseudomonas aeruginosa (19 %),
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and Klebsiella pneumonia (19 %) were isolated in three
cases each of CAUTI.
The overall incidence of the three DA-HAIs per 1000
patient-days was 11.2. The rates per 100 patients and
per 1000 device-days are provided in Table 2.
Table 1 shows a comparison of the data for the patients
with and without DA-HAIs. The mean PIM2 of the
patients with DA-HAIs was 6.3 %, which was higher than
that of the patients without DA-HAIs (3.5 %). The median
duration of PICU stay for the patients with DA-HAIs was
22.5 days, compared with 2 days for those without DA-
HAIs. The actual mortality of the patients with DA-HAIs
was 7.1 %, which was worse than the predicted mortality
(PIM2) of 6.3 %, whereas the actual mortality of the
patients without DA-HAIs was 2.3 %, which was better
than the predicted mortality of 3.5 %. The SMR of the
patients with DA-HAIs was 1.13 (95 % CI 0.47–4.33),
whereas that of the patients without DA-HAIs was 0.64
(95 % CI 0.33–1.25). However, there was no statistically
significant difference in the SMR between the two groups.
The numbers of the patients with and without VAP
for the patients who had an uncuffed and a cuffed ETT
are provided in Table 3.
Discussion
To our knowledge, this is the first surveillance study to
show the incidences of three common DA-HAIs in a PICU
in Japan. In our study, 6.6 % of the patients admitted to the
PICU developed one of three common DA-HAIs; this rate
was lower than the incidences in developing countries
(15.5–24.5 %) [2, 8, 9] and was within a similar range of the
incidences in other developed countries (6.0–23.6 %), which
included other types of DA-HAIs [1, 4–7]. In our study, the
incidence of the three common DA-HAIs per 1000 patient-
days was 11.2, which was lower than incidences reported in
other studies in developing countries of 18.6–26.3 [2, 8, 9].
The incidences of CLABSI, VAP, and CAUTI per 1000
device-days were 4.3, 3.5, and 13.6, respectively. The
incidences of CLABSI and VAP were within similar
ranges of those in other developed countries (CLABSI
Table 1 Characteristics of patients, mortality, and length of PICU stay with and without DA-HAIs
All With DA-HAIs Without DA-HAIs P
(n = 426) (n = 28) (n = 398)
Age months, median (25th; 75th percentile) 12 (2.5; 48.5) a 4 (1; 22) a 13 (3; 54) a 0.014
Gender M/F 206/220 11/17 195/203 0.32
Elective surgery n (%) 261 (61.3) 10 (35.7) 251 (63.1) 0.0041
Unplanned admission n (%) 140 (32.9) 15 (53.6) 125 (31.4) 0.016
With infection at admission n (%) 71 (16.7) 4 (14.3) 67 (16.8) 0.73
PIM2 (%) 3.7 6.3 3.5 <0.0001
[mean (95% CI)] (3.0–4.4) (3.5–9.2) (2.7–4.3)
Device utilization ratio
CVC 0.78 0.93 0.74 -
ETT 0.53 0.64 0.51 -
UC 0.44 0.56 0.40 -
Mortality 28 d, % (n) 2.6 (11) 7.1 (2) 2.3 (9) 0.16
Length of PICU stay, median 3 22.5 2 <0.001
(25th; 75th percentile) (1; 7) a (13; 32.75) a (1; 6) a
PIM2 Pediatric Index of Mortality 2, DA-HAIs device-associated healthcare-associated infections, CVC central venous catheter, ETT endotracheal tube, UC urinary
catheter, Mortality 28d mortality 28 days after discharge from the PICU
aNumbers in parentheses: 25th percentile; 75th percentile









Rate per 1000 device-days
CLABSI 2089 9 2.1 4.3
VAP 1428 5 1.2 3.5
CAUTI 1173 16 3.8 13.6
DA-HAI device-associated healthcare-associated infection, CLABSI central line-associated bloodstream infection, VAP ventilator-associated pneumonia, CAUTI
catheter-associated urinary tract infection
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2.0–8.5 [10, 13, 15]; VAP 1.8–17.1 [10, 16, 19]).
However, Patrick SW et al. recently reported a great
decrease and extremely low incidences of DA-HAIs.
They reported a decrease in the incidence of CLABSI
from 4.7 to 1.0 and incidence of VAP from 1.9 to 0.7
per 1000 device-days from 2007 to 2012 [23]. The
authors stressed the importance of data feedback to reduce
DA-HAIs. This study suggested that we should continue
this surveillance, and there is scope for improvement in the
incidences of DA-HAIs in our PICU.
The incidence of VAP was particularly low in our study.
In our PICU, prone positioning is frequently used to
prevent atelectasis and VAP. This may have reduced the
incidence of VAP, or at least of atelectasis. According to
the CDC/NHSN surveillance definitions, pneumonia is
defined when there is new or progressive and persistent
infiltrate, consolidation, cavitation, or pneumatoceles [22].
Pulmonary infection is difficult to differentiate from
noninfective nfiltrates such as atelectasis. Therefore,
reducing noninfective infiltrates may contribute to a
reduction in false positive diagnoses of VAP. We used a
cuffed ETT for some patients and an uncuffed ETT for
the others. There was a possibility that a cuffed ETT
had prevented VAP. Among the patients who had a cuffed
ETT, no patient acquired VAP, whereas among the patients
who had an uncuffed ETT, five patients acquired VAP.
However, there was no statistically significant difference
observed (P = 0.36). Further studies are warranted.
The incidence of CLABSI was within a similar range
of that in other countries although the device utilization
ratio per patients-days for CVCs (0.78) was higher than
that of other studies (0.46–0.67) [2, 8]. E. Goes-Silva
et al. reported that use of peripherally inserted central
catheters had prevented CLABSI in children [24]. We
frequently used peripherally inserted central catheters.
The total device-days for peripherally inserted central
catheter were 1348 days compared to these for CVC of
2089 days. There was a possibility that these catheters
had prevented CLABSI.
The incidence of CAUTI was 13.6 per 1000 device-days,
and unlike CLABSI and VAP, this was relatively higher
than the incidences in other studies of 5.1–5.8 [2, 8, 10].
The high device utilization ratio of UC (0.44), compared
with that reported in other studies (0.25–0.36) [2, 8], may
have been associated with our high incidence of CAUTI.
Therefore, we think that implementation of daily assess-
ments of the necessity for each device is desirable.
Younger age, lower percentage of elective surgery
patients, higher percentage of unplanned admission
patients, and higher PIM2 were all observed in the
patients with DA-HAIs. Younger age has been reported to
be a risk factor for DA-HAIs in previous studies [2, 4, 6].
In our study, the risk of DA-HAIs for elective surgery
patients was lower than that for the other patients (35.7 vs.
63.1 % P = 0.0041), whereas it was higher for unplanned
admission patients than for planned admission patients
(53.6 vs. 31.4 % P = 0.016). Becerra et al. showed a similar
trend [2], but this result is controversial [6, 24]. In regards
to PIM2, in our study, mean PIM2 among the patients with
DA-HAIs was higher than that among the patients without
DA-HAIs. However, Becerra et al. reported that there was
no difference in pediatric risk of mortality score, another
method for predicting mortality in pediatric patients,
between the patients with and without DA-HAIs [2]. We
speculate that nonelective surgery patients, unplanned
admission patients, and higher PIM2 patients are at high
risk of DA-HAIs because of the high density of invasive
therapeutic interventions on admission, which means
higher device utilization ratio and prolonged PICU stay,
resulting in higher infection rate [25]. However, further
studies are warranted.
Of the 426 patients admitted to the PICU, 71 patients
had any type of infection at admission to the PICU. There
were four patients (14.3 %) who had infection at admission
among the 28 patients with DA-HAIs, comparable to 67
patients (16.8 %) among the 398 patients without DA-
HAIs. There was no statistically significant difference
observed (P = 0.73). Therefore, an incidence of DA-HAIs
was not influenced by whether an infection was present at
admission or not.
In our study, coagulase-negative Staphylococci were the
most common pathogens in CLABSI. This was reported
previously [2, 4]. In our study, there were only five cases of
VAP, and we found no trend in isolated pathogen. Previous
studies have reported that Pseudomonas aeruginosa was
the most common pathogen in VAP [2, 4]. In our study,
Escherichia coli, Pseudomonas aeruginosa, and Klebsiella
pneumonia were the most common pathogens in CAUTI.
A previous study has reported that these aerobic
Gram-negative pathogens were frequently observed in
CAUTI [4].
In our study, although the patients’ profiles were different
between the groups, the median length of PICU stay of
22.5 days for the patients with DA-HAIs was much longer
than that of 2 days for the patients without DA-HAIs, as
expected. Another study also showed an increased length
of PICU stay with DA-HAIs [2]. However, we cannot differ-
entiate whether this longer stay was a cause or a result of
the DA-HAIs.
Table 3 The numbers of patients with and without VAP for
patients who had uncuffed and cuffed ETT
All With VAP Without VAP P
(n = 318) (n = 5) (n = 313)
Uncuffed ETT n 260 5 255
Cuffed ETT n 58 0 58 0.36
VAP ventilator-associated pneumonia, ETT endotracheal tube
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The SMR of the patients with DA-HAIs was 1.13 (95 %
CI 0.47–4.33), whereas that of the patients without DA-
HAIs was 0.64 (95 % CI 0.33–1.25). However, in our study,
there was no statistically significant difference in the SMR
between the two groups. Becerra et al. showed increased
mortality of patients with DA-HAIs [2]. Further studies are
required to confirm this.
There were some limitations to our study. First, we
studied only three common types of DA-HAIs (CLABSI,
VAP, and CAUTI). Previous studies reported that these
three types of DA-HAIs represented 64–88 % of all
reported infections [4, 5]. Therefore, the actual overall
incidence of DA-HAIs may be higher than we have
reported. Surveillance of other types of DA-HAIs, such as
surgical site infection, eye, ear, nose and throat infection,
and cardiovascular infection, should be considered in the
future. Second, we studied only a single PICU for a year.
These data may not adequately reflect the entire situation
in Japan, and a continuous multicenter surveillance study
is necessary. Third, our study was retrospective, relying on
past medical records and data for which the accuracy and
completeness was not validated. Therefore, diagnosis of
DA-HAIs for some patients may have been overlooked.
Fourth, the backgrounds of the patients with and without
DA-HAIs were much different, particularly in PIM2.
Although PIM2 has been originally developed to predict
the death of groups, not of individual patients, when we
only investigated patients with PIM2 < 2.5 %, who might
have had low risk and were expected to stay for a shorter
duration, the median length of PICU stay for the patients
with DA-HAIs was 24 days [25th percentile 11.5; 75th
percentile 36.5], compared with 2 days [1; 4] for those
without DA-HAIs (P < 0.0001). Therefore, when we
investigated only patients with PIM2 < 2.5 %, there was
a difference in the length of PICU stay for the patients
with and without DA-HAIs.
Conclusions
This study showed the incidences of three common DA-
HAIs (CLABSI, VAP, and CAUTI) in a PICU in Japan.
These DA-HAIs were associated with longer length of
PICU stay.
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